Clinical trials: PARKINSON DISEASE (Disorder)
Parkinson Disease
Efficacy, Safety and Tolerability of PF-06649751 in Parkinson's Disease Patients With Motor Fluctuations
The purpose of this study is to evaluate the efficacy, safety and tolerability of PF-06649751 in Parkinson's disease patients who experience motor-fluctuations.
- Trial name
- NCT02687542
- Testing
- PF-06649751 low dose (1 mg QD), PF-06649751 middle dose 1 (3 mg QD), PF-06649751 middle dose 2 (7 mg QD)
- Where
- 57 sites in United States, Canada and 4 more
- Volunteers
- 108 people
- Sponsor
- Pfizer
Parkinson's Disease (PD)
Tolerability, Pharmacokinetics and Pharmacodynamics of BIA 9-1067
The purpose of this study is to assess the tolerability of BIA 9-1067 after multiple rising dose regimens of BIA 9-1067.
- Trial name
- NCT02071810
- Testing
- BIA 9-1067
- Where
- France
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Bial - Portela C S.A.
Parkinson's Disease, Cognitive Impairment
Memantine for Treatment of Cognitive Impairment in Patients With Parkinson's Disease and Dementia
The purpose of this research is to evaluate the usefulness of memantine, compared to placebo (sugar pill), for the treatment of cognitive impairment in patients with idiopathic Parkinson's disease (PD) and dementia.
- Conditions
- Parkinson's Disease, Cognitive Impairment, Dementia
- Trial name
- NCT00294554
- Testing
- Memantine
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Johns Hopkins University
Melanoma
Safety and Efficacy of Pembrolizumab Compared to Placebo in Resected High-risk Stage II Melanoma (MK-3475-716/KEYNOTE-716)
This 2-part study will evaluate the safety and efficacy of pembrolizumab (MK-3475) compared to placebo in participants with surgically resected high-risk Stage II melanoma.
- Trial name
- NCT03553836
- Testing
- Pembrolizumab
- Where
- 159 sites in United States, Australia and 14 more
- Volunteers
- 976 people
- Sponsor
- Merck Sharp & Dohme LLC
Parkinson Disease
Study to Assess PDM608 in Healthy Adult Subjects
The purpose of this study is to assess the safety, tolerability and pharmacokinetics of PDM608 in healthy adult subjects.
- Trial name
- NCT05950906
- Testing
- PDM608
- Where
- United States
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Calibr, a division of Scripps Research
Parkinson's Disease
A Dose-ranging Study for SPM 962 in Parkinson's Disease Patients
The primary objective of this trial is to establish the maximum maintenance dose of SPM 962 in patients with Parkinson's disease in a multi-center, uncontrolled, open-label study by conducting safety evaluation of each patient…
- Trial name
- NCT01634243
- Testing
- SPM 962
- Where
- 5 sites in Japan
- Volunteers
- 64 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Parkinson Disease, Amyotrophic Lateral Sclerosis
Study of AMDX-2011P as a Retinal Tracer in Subjects With Neurodegenerative Diseases Associated With Amyloidogenic Proteinopathy
The purpose of this research study is to assess safety and tolerability of a single intravenous (given through a vein) dose of the investigational retinal tracer AMDX-2011P in patients with neurodegenerative diseases (Parkinson's…
- Trial name
- PROBE (NCT05542576)
- Testing
- AMDX2011P
- Where
- 2 sites in United States
- Volunteers
- 13 people
- Sponsor
- Amydis Inc.
Triple Negative Breast Neoplasms
Study of Olaparib Plus Pembrolizumab Versus Chemotherapy Plus Pembrolizumab After Induction With First-Line Chemotherapy Plus Pembrolizumab in Triple Negative Breast Cancer (TNBC) (MK-7339-009/KEYLYNK-009)
The purpose of this study is to compare the efficacy of olaparib (MK-7339) plus pembrolizumab (MK-3475) with chemotherapy plus pembrolizumab after induction with first-line chemotherapy plus pembrolizumab in triple negative…
- Trial name
- NCT04191135
- Testing
- Pembrolizumab, Olaparib, Carboplatin
- Where
- 122 sites in United States, Canada and 13 more
- Volunteers
- 462 people
- Sponsor
- Merck Sharp & Dohme LLC
Parkinson Disease
Clinical Trial to Evaluate the Safety and Tolerability of Hydrogen in Patients With Parkinson's Disease
This study is a placebo-controlled, double-blind trial that will investigate the safety and tolerability of molecular hydrogen, a promising antioxidant agent, in patients with early-stage Parkinson's Disease.
- Trial name
- NCT03971617
- Testing
- Hydrogen
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Stony Brook University
Parkinson Disease
Open-Label Extension Study With REQUIP PR for Subjects From Study ROP111528
This open label extension study allows assessment of the long term safety profile of REQUIP PR in subjects who have completed 24 weeks of randomised treatment in study ROP111528.
- Trial name
- NCT01536574
- Testing
- Requip PR
- Where
- 18 sites in China
- Volunteers
- 295 people
- Sponsor
- GlaxoSmithKline
Parkinson Disease
Cognitive Training in Parkinson's Disease
The purpose of this research study is to determine whether cognitive training will improve cognitive and brain functions in people with Parkinson's Disease (PD) during activities of daily living using cognitive evaluations and…
- Trial name
- NCT05495997
- Testing
- Mental Imagery Training, Psychoeducation
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Yale University
Parkinson's Disease
Efficacy, Safety and Tolerability of E2007 in Levodopa Treated Parkinson's Disease Patients With Motor Fluctuations
Randomised, double-blind, double dummy, parallel group design. Following the screening period patients will be randomised at the baseline visit, in a 1:1:1 manner, to one of three treatment arms; 4 mg E2007, 200 mg entacapone…
- Trial name
- NCT00360308
- Testing
- E2007
- Where
- France
- Volunteers
- 723 people
- Sponsor
- Eisai Limited
Parkinson Disease
Acute Effects of Preladenant (SCH 420814) on Dyskinesia and Parkinsonism in Levodopa Treated Participants (P05550)
This is a randomized, placebo-controlled, 3-period crossover, balanced, single-site, third party-blind study of preladenant (SCH 420814) in participants with Parkinson disease (PD) to be conducted in conformance with Good…
- Trial name
- NCT00845000
- Testing
- SCH 420814 10 mg, SCH 420814 100 mg, Levodopa
- Volunteers
- 12 people
- Sponsor
- Merck Sharp & Dohme LLC
Parkinson's Disease
Evaluation of Long-term Effect of Resonator Therapy on Parkinson's Disease (PD)
An extension study for subjects with prior participation in previous resonator studies using low level magnetic fields to treat some of the symptoms of idiopathic Parkinson's Disease.
- Trial name
- NCT00862537
- Testing
- Resonator Device
- Volunteers
- 18 people
- Sponsor
- pico-tesla Magnetic Therapies, LLC
Parkinson Disease
A Clinical Study Evaluating Efficacy of Pirepemat on Falls Frequency in Patients With Parkinson's Disease (PD)
This is a Phase 2b study investigating the efficacy and safety of pirepemat as adjunct therapy on falls frequency in patients with Parkinson disease. Pirepemat is taken for 84 days.
- Trial name
- NCT05258071
- Testing
- Pirepemat
- Where
- 37 sites in France, Germany and 4 more
- Volunteers
- 104 people
- Sponsor
- Integrative Research Laboratories AB
Parkinson's Disease
A Double-blind Study to Evaluate the Safety of Glutamic Acid Decarboxylase Gene Transfer in Parkinson's Participants
The objective of this clinical trial was to evaluate the safety and tolerability of adeno-associated virus (AAV)-mediated delivery of glutamic acid decarboxylase (GAD) gene transfer into the subthalamic nuclei (STN) of…
- Trial name
- NCT05603312
- Testing
- AAV-GAD Low Dose, AAV-GAD High Dose
- Where
- 6 sites in United States
- Volunteers
- 14 people
- Sponsor
- MeiraGTx, LLC
Parkinson Disease
EMPOWER PD - Feasibility of an Interdisciplinary Clinic for People With Parkinson's Disease
This study is a nonrandomized, pilot study of an interdisciplinary, patient-centric model of health care delivery in a "boot camp" style structured clinic for people diagnosed with Parkinson's disease (PwPD).
- Trial name
- NCT05640167
- Testing
- Interdisciplinary Clinic
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- University of Rhode Island
Parkinson's Disease Psychosis
A Study of the Safety and Efficacy of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis
This study will evaluate the safety and efficacy of two dose levels of pimavanserin (ACP-103) compared to placebo in patients with Parkinson's disease psychosis.
- Trial name
- NCT00477672
- Testing
- Pimavanserin tartrate (ACP-103)
- Where
- 78 sites in United States, Bulgaria and 5 more
- Volunteers
- 298 people
- Sponsor
- ACADIA Pharmaceuticals Inc.
Parkinson Disease, Idiopathic Parkinson Disease
An Active-Controlled Extension Study to NCT01155466 [P04938] and NCT01227265 [P07037] (P06153)
The primary purpose of this extension study is to assess the long-term safety and tolerability of preladenant in participants from parent studies NCT01155466 [P04938] and NCT01227265 [P07037] with moderate to severe Parkinson's…
- Trial name
- NCT01215227
- Testing
- Preladenant, Rasagiline
- Volunteers
- 839 people
- Sponsor
- Merck Sharp & Dohme LLC
Parkinson Disease
PS128 May Improve Off Duration on Parkinson's Disease
The purpose of this study is to investigate the short term effects (12 Weeks) of Lactobacillus plantarum PS128 (PS128) on Parkinson's disease (PD) symptoms.
- Trial name
- NCT04389762
- Testing
- daily ingestion of Lactobacillus plantarum PS128
- Where
- Taiwan
- Volunteers
- 26 people
- Sponsor
- Professor Lu Neurological Clinic